|
1
|
Stintzing S, Stremitzer S, Sebio A and
Lenz HJ: Predictive and prognostic markers in the treatment of
metastatic colorectal cancer (mCRC): Personalized medicine at work.
Hematol Oncol Clin North Am. 29:43–60. 2015. View Article : Google Scholar
|
|
2
|
Adjei AA: Blocking oncogenic Ras signaling
for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoon HH, Tougeron D, Shi Q, Alberts SR,
Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent
DJ, et al: KRAS codon 12 and 13 mutations in relation to
disease-free survival in BRAF wild-type stage III colon cancers
from an adjuvant chemo-therapy trial (N0147 alliance). Clin Cancer
Res. 20:3033–3043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patricelli MP, Janes MR, Li LS, Hansen R,
Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, et al:
Selective inhibition of oncogenic KRAS output with small molecules
targeting the inactive state. Cancer Discov. 6:316–329. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lito P, Solomon M, Li LS, Hansen R and
Rosen N: Allele-specific inhibitors inactivate mutant KRAS G12C by
a trapping mechanism. Science. 35:604–608. 2016. View Article : Google Scholar
|
|
6
|
Janes MR, Zhang J, Li LS, Hansen R, Peters
U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, et al:
Targeting KRAS mutant cancers with a covalent G12C-specific
inhibitor. Cell. 172:578–589.e17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garcia Fortanet J, Chen CH, et al:
Allosteric inhibition of SHP2: Identification of a potent,
selective, and orally efficacious phosphatase inhibitor. J Med
Chem. 59:7773–7782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen YN, LaMarche MJ, Chan HM, Fekkes P,
Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke
VG, et al: Allosteric inhibition of SHP2 phosphatase inhibits
cancers driven by receptor tyrosine kinases. Nature. 535:148–52.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu H, Liu C, Velazquez R, Wang H, Dunkl
LM, Kazic-Legueux M, Haberkorn A, Billy E, Manchado E, Brachmann
SM, et al: SHP2 Inhibition overcomes RTK-mediated pathway
reactivation in KRAS-mutant tumors treated with MEK inhibitors. Mol
Cancer Ther. 18:1323–1334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamaguchi T, Kakefuda R, Tajima N, Sowa Y
and Sakai T: Antitumor activities of JTP-74035(GSK1120212), a novel
MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in
vivo. Int J Oncol. 39:23–21. 2011.PubMed/NCBI
|
|
11
|
Gilmartin AG, Bleam MR, Groy A, Moss KG,
Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang
J, et al: GSK1120212(JTP-74057) is an inhibitor of MEK activity and
activation with favorable pharmacologic properties for sustained in
vivo pathway inhibition. Clin Cancer Res. 17:989–1000. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kirkwood JM, Bastholt L, Robert C, Sosman
J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V,
Kemsley K and Dummer R: Phase II, open-label, randomized trial of
the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide
in patients with advanced melanoma. Clin Cancer Res. 18:555–567.
2012. View Article : Google Scholar
|
|
14
|
Adjei AA, Cohen RB, Franklin W, Morris C,
Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, et al:
Phase I pharmacokinetic and pharmacodynamics study of the oral,
small-molecule mitogen-activated protein kinase kinase 1/2
inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
J Clin Oncol. 26:2139–2146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Infante JR, Fecher LA, Nalllapareddy S,
Gordon MS, Flaherty KT, Cox DS, DeMarini DJ, Morris SR, Burris HA
and Messersmith WA: Safety and efficacy results from the
first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J
Clin Oncol. 28(15_Suppl): S25032010. View Article : Google Scholar
|
|
16
|
Bennouna J, Lang I, Valladares-Ayerbes M,
Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD and
Douillard JY: A phase II, open-label, randomised study to assess
the efficacy and safety of the MEK1/2 inhibitor AZD6244
(ARRY-142886) versus capecitabine monotherapy in patients with
colorectal cancer who have failed one or two prior chemotherapeutic
regimens. Invest New Drugs. 29:1021–1028. 2011. View Article : Google Scholar
|
|
17
|
Zhao Y and Adjei AA: The clinical
development of MEK inhibitors. Nat Rev Clin Oncol. 11:385–400.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ascierto PA, Ferrucci PF, Fisher R, Del
Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV,
Di Giacomo AM, et al: Darafenib, trametinib and pembrolizumab or
placebo in BRAF-mutant melanoma. Nat Med. 25:941–946. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan N, Wong M, Nannini MA, Hong R, Lee LB,
Price S, Williams K, Savy PP, Yue P, Sampath D, et al: Bcl-2/Bcl-xl
inhibition increases the efficacy of MEK inhibition alone and in
combination with PI3 kinase inhibition in lung and pancreatic tumor
models. Mol Cancer Ther. 12:853–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong Y, Somwar R, Politi K, Balak M,
Chmielecki J, Jiang X and Pao W: Induction of BIM is essential for
apoptosis triggered by EGFR kinase inhibitors in mutant
EGFR-dependent lung adenocarcinomas. PLoS Med. 4:e2942007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hata AN, Yeo A, Faber AC, Lifshits E, Chen
Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, et al:
Failure to induce apoptosis via BCL-2 family proteins underlies
lack of efficacy of combined MEK and PI3K inhibitors for
KRAS-mutant lung cancers. Cancer Res. 74:3146–3156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Willis SN, Wei A, Smith BJ,
Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC:
Differential targeting of prosurvival Bcl-2 proteins by their
BH3-only ligands allows complementary apoptotic function. Mol Cell.
17:393–403. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawabata T, Tanimura S, Asai K, Kawasaki
R, Matsumaru Y and Kohno M: Up-regulation of pro-apoptotic protein
Bim and downregulation of anti-apoptotic protein Mcl-1
cooperatively mediate enhanced tumor cell death induced by the
combination of ERK kinase (MEK) inhibitor and microtubule
inhibitor. J Biol Chem. 287:10289–10300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meng J, Fang B, Liao Y, Chresta CM, Smith
PD and Roth JA: Apoptosis induction by MEK inhibition in human lung
cancer cells is mediated by Bim. PLoS One. 5:e130262010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Corcoran RM, Cheng KA, Hata AN, Faber AC,
Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, et
al: Synthetic lethal interaction combined BCL-XL and MEK inhibition
promotes tumor regressions in KRAS mutant cancer models. Cancer
Cell. 14:121–128. 2013. View Article : Google Scholar
|
|
26
|
Scherr AL, Gdynia G, Salou M,
Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A,
Elssner C, et al: Bcl-xl is an oncogenic driver in colorectal
cancer. Cell Death Dis. 7:e23422016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zaanan A, Okamoto K, Kawakami H, Khazaie
K, Huang S and Sinicrope FA: Mutant KRAS upregulates BCL-XL via
STAT3 to confer apoptosis resistance that is reversed by BIM
induction and BCL-XL antagonism. J Biol Chem. 290:23838–23849.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kitazawa M, Hida S, Fujii C, Taniguchi S,
Ito K, Matsumura T, Okada N, Sakaizawa T, Kobayashi A, Takeoka M
and Miyagawa SI: ASC induces apoptosis via activation of caspase-9
by enhancing gap junction-mediated intercellular communication.
PLoS One. 12:e01693402017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Soikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cho SY, Han JY, Na D, Kang W, Lee A, Kim
J, Lee J, Min S, Kang J, Chae J, et al: A novel combination
treatment targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and
BCL2L1-amplified colorectal cancers. Mol Cancer Ther. 16:2178–2190.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ahmed D, Eide PW, Eilertsen IA, Danielsen
SA, Eknæs M, Hektoen M, Lind GE and Lothe RA: Epigenetic and
genetic features of 24 colon cancer cell lines. Oncogenesis.
16:e712013. View Article : Google Scholar
|
|
37
|
Kasper S, Breitenbuecher F, Reis H,
Brandau S, Worm K, Köhler J, Paul A, Trarbach T, Schmid K and
Schuler M: Oncogenic RAS simultaneously protects against anti-EGFR
antibody-dependent cellular cytotoxicity and EGFR signaling
blockade. Oncogene. 32:2873–2881. 2013. View Article : Google Scholar
|
|
38
|
Welsh SJ and Corrie PG: Management of BRAF
and MEK inhibitor toxicities in patients with metastatic melanoma.
Ther Adv Med Oncol. 7:122–1236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tutusaus A, Stefanovic M, Boix L, et al:
Antiapoptotic BCL-2 proteins determine Sorafenib/regorafenib
resistance and BH3-mimetic efficacy in hepatocellular carcinoma.
Oncotarget. 30:16701–16717. 2018. View Article : Google Scholar
|
